906. Impact on Patient Outcomes of Pan-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia
Session: Poster Abstract Session: Respiratory Infections
Friday, October 4, 2013
Room: The Moscone Center: Poster Hall C
Posters
  • idweek2013act.pdf (1001.8 kB)
  • Background:

    The objective of this study was to determine the impact of ventilator-associated pneumonia caused by pan-resistant Acinetobacter baumannii on patient outcomes.

    Methods:

    Clinical parameters and overall in-hospital mortality rates were compared between patients with ventilator-associated pneumonia due to pan resistant A. baumannii and those with ventilator-associated pneumonia due to non pan-resistant A. baumannii.

    Results:

    One hundred and thirty-four (79 males and 55 females; mean age: 53.2±21 yrs) with ventilator-associated pneumonia caused by A. baumannii were identified. Simplified acute physiology score II (SAPS II) were higher in the patients with pan-resistant A. baumannii infection compared to non pan-resistant A. baumannii at the time of ventilator-associated pneumonia diagnosis (p=0.034). Mean of hospital stay before the onset of ventilator-associated pneumonia was 17.9±11.6 days. The rate of ventilator-associated pneumonia caused by pan-resistant A. baumannii was 25.4% and the incidence of pan-resistant A. baumannii increased from 8.6% (study period I) to 43.8% (study period II) (p<0.005). Ventilator-associated pneumonia caused by pan-resistant A. baumannii was not associated with in-hospital mortality (p=0.858). However, it was a risk factor, increasing length of stay in the ICU and in hospital (21.7±11.9 vs. 30.4±17.9 days, p=0.005 and 27.8±13.2 vs. 39.0±18.9 days, p=0.001, respectively).

    Conclusion:

    This study showed that the rate of ventilator-associated pneumonia caused by pan-resistant A. baumannii significantly increased in recent years. It was related to high SAPS II scores and increasing durations of ICU and hospital stays.

    Elif Sahin Horasan, MD1, Eylem Sercan Ozgür2, Kerem Karaca3, Sibel Atis Nayci4, Gülden Ersöz4 and Ali Kaya4, (1)Department of Infectious Diseases, Mersin University, Faculty of Medicine, Mersin, Turkey, (2)Respiratory Disease, Mersin, Turkey, (3)Cardiovascular Diseases, Mersin, Turkey, (4)Mersin University, mersin, Turkey

    Disclosures:

    E. S. Horasan, None

    E. Sercan Ozgür, None

    K. Karaca, None

    S. Atis Nayci, None

    G. Ersöz, None

    A. Kaya, None

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.